OBJECTIVE: To evaluate the effects of weight loss on endocannabinoids, cardiometabolic and psychological parameters, eating disorders (ED) as well as quality of life (QoL) and to elucidate the role of endocannabinoids in metabolic syndrome (MS). METHODS: In total, 114 patients with obesity were prospectively included in a 12-month weight loss program. Plasma endocannabinoids were measured by mass spectrometry; ED, psychological and QoL-related parameters were evaluated by self-reported questionnaires; physical activity was measured by accelerometer. Nutritional assessment was done by a 3-day food diary. RESULTS: Among completers (n = 87), body weight decreased in 35 patients (-9.1 ± 8.6 kg), remained stable in 39 patients, and increased in 13 patients (+5.8 ± 3.4 kg). 75% of patients with MS at baseline were free of MS at follow-up, and their baseline plasma N-palmitoylethanolamide (PEA) values were significantly lower when compared to patients with persisting MS. At baseline, there was a positive relationship between PEA and waist circumference (p = 0.005, R2 = 0.08), fasting glucose (p < 0.0001, R2 = 0.12), total cholesterol (p = 0.001, R2 = 0.11), triglycerides (p = 0.001, R2 = 0.11), LDL-cholesterol (p = 0.03, R2 = 0.05) as well as depression score (p = 0.002, R2 = 0.29). CONCLUSION: Plasma PEA might play a role in metabolic improvement after weight loss. Even in subjects without weight loss, a multidisciplinary intervention improves psychological outcomes, ED, and QoL.
OBJECTIVE: To evaluate the effects of weight loss on endocannabinoids, cardiometabolic and psychological parameters, eating disorders (ED) as well as quality of life (QoL) and to elucidate the role of endocannabinoids in metabolic syndrome (MS). METHODS: In total, 114 patients with obesity were prospectively included in a 12-month weight loss program. Plasma endocannabinoids were measured by mass spectrometry; ED, psychological and QoL-related parameters were evaluated by self-reported questionnaires; physical activity was measured by accelerometer. Nutritional assessment was done by a 3-day food diary. RESULTS: Among completers (n = 87), body weight decreased in 35 patients (-9.1 ± 8.6 kg), remained stable in 39 patients, and increased in 13 patients (+5.8 ± 3.4 kg). 75% of patients with MS at baseline were free of MS at follow-up, and their baseline plasma N-palmitoylethanolamide (PEA) values were significantly lower when compared to patients with persisting MS. At baseline, there was a positive relationship between PEA and waist circumference (p = 0.005, R2 = 0.08), fasting glucose (p < 0.0001, R2 = 0.12), total cholesterol (p = 0.001, R2 = 0.11), triglycerides (p = 0.001, R2 = 0.11), LDL-cholesterol (p = 0.03, R2 = 0.05) as well as depression score (p = 0.002, R2 = 0.29). CONCLUSION: Plasma PEA might play a role in metabolic improvement after weight loss. Even in subjects without weight loss, a multidisciplinary intervention improves psychological outcomes, ED, and QoL.
Authors: Uma Mudaliar; Azadeh Zabetian; Michael Goodman; Justin B Echouffo-Tcheugui; Ann L Albright; Edward W Gregg; Mohammed K Ali Journal: PLoS Med Date: 2016-07-26 Impact factor: 11.069
Authors: Jennifer A Schrack; Ryan J Dougherty; Abigail Corkum; Fangyu Liu; Amal A Wanigatunga Journal: Curr Hypertens Rep Date: 2022-06-13 Impact factor: 4.592
Authors: Phillipa Hay; Marly Amorim Palavras; Felipe Quinto da Luz; Sérgio Dos Anjos Garnes; Amanda Sainsbury; Stephen Touyz; José Carlos Appolinario; Angélica Medeiros Claudino Journal: BMC Psychiatry Date: 2022-05-24 Impact factor: 4.144
Authors: Lea Tischmann; Mathijs Drummen; Peter J Joris; Blandine Gatta-Cherifi; Anne Raben; Mikael Fogelholm; Isabelle Matias; Daniela Cota; Ronald P Mensink; Margriet S Westerterp-Plantenga; Tanja C Adam Journal: Nutrients Date: 2020-05-22 Impact factor: 5.717